Indegene Q2 FY27 Results: Key Dates for All Investors

Results schedule sets the next investor milestone

Indegene Limited has set out the schedule for its second-quarter FY27 financial disclosures and investor interaction. The company’s board of directors is scheduled to meet on October 29, 2026, to consider unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Indegene has said the results will be released after market hours on the same day. This will be followed by a Q2 FY27 earnings call at 8:00 AM IST on October 30, 2026. The sequence gives investors an opportunity to review the reported figures before management discusses the quarter. The announcement was made under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements regulations.

Board to consider quarterly and half-year numbers

The October 29 board meeting is expected to consider both standalone and consolidated unaudited financial statements. The agenda also includes the limited review report issued by the company’s auditors for the relevant period. The reported period covers the July-September quarter, which is the second quarter of Indegene’s April-March financial year. It also covers the first six months ending September 30, 2026. Standalone results reflect the listed entity’s financial performance, while consolidated results include its subsidiaries and other entities covered under applicable accounting rules. Investors will be able to compare these disclosures with the company’s first-quarter performance once the results are filed with the exchanges.

Earnings call planned for October 30

Indegene has scheduled its Q2 FY27 earnings call for October 30 at 8:00 AM IST. The company’s investor-relations update says Chairman and Chief Executive Officer Manish Gupta and Chief Financial Officer Suhas Prabhu will participate in the call. The session is intended for investors and analysts seeking management commentary after the financial results are released. The company has provided dial-in arrangements for remote participation. A recording and transcript were not available at the time of the announcement. Such calls typically provide context on reported financial performance, client activity, operating priorities and outlook-related commentary, although the company has not pre-announced the subjects it will address.

Key dates and disclosures

First-quarter performance provides context

The upcoming release follows Indegene’s Q1 FY27 update in July 2026. In its investor presentation, the company reported revenue of ₹1,063.1 crore for the June 2026 quarter, representing year-on-year growth of 39.7%. It reported an EBITDA margin of 16.9% for that quarter. The presentation also described a strategy focused on scaling generative AI-powered solutions and deepening engagement with large pharmaceutical companies. These metrics form the immediate base for sequential comparison when September-quarter numbers are released. However, Indegene has not provided Q2 financial figures in the earnings-call intimation, so any assessment of growth or margins will depend on the October 29 filing.

Why standalone and consolidated data matter

The availability of both standalone and consolidated financial results is relevant for a company operating through a broader group structure. Consolidated reporting offers a view of the financial performance across entities included in the group accounts. Standalone reporting, by contrast, isolates the listed company’s own performance. Differences between the two can arise from operations conducted through subsidiaries, inter-company transactions and consolidation adjustments. The limited review report will indicate the auditors’ review of the unaudited results under the applicable reporting framework. Investors generally examine both sets of statements alongside segment details and management commentary, where disclosed, to understand the sources of revenue and profitability.

Focus remains on revenue growth and margins

Indegene’s July investor presentation placed its first-quarter revenue growth and margin profile in focus. The company reported a 16.9% EBITDA margin in Q1 FY27 and indicated an expectation of margin recovery to 19%-20% by the fourth quarter, according to the presentation summary. The September-quarter result will therefore be watched for disclosed changes in revenue growth, operating margin and costs. It will also provide the next formal update on the company’s work with pharmaceutical clients and its technology-led service offerings. No share-price movement or market reaction is contained in the announcements. As a result, the present disclosure is primarily a calendar update rather than an indication of financial performance.

Regulatory disclosure supports investor access

The earnings-call intimation was filed under Regulation 30 of the LODR framework, which requires listed companies to disclose specified material events to stock exchanges. The board-meeting notice separately informs the market about the planned consideration of quarterly and half-yearly results. Together, these disclosures establish the timetable for the financial update and the associated management interaction. Indegene had also filed an analyst presentation and fact sheet for the quarter ended June 30, 2026, following its first-quarter results. Its investor-relations page lists financial results, presentations, call transcripts and annual reports among the materials available to shareholders. This structure allows investors to review official documents alongside the scheduled conference call.

What investors can track next

The immediate event is the release of Indegene’s Q2 FY27 results after market hours on October 29. Investors can then assess the audited-review documentation, reported revenue, profitability measures and any accompanying presentation against the June-quarter base. The management call the following morning is expected to provide an opportunity for questions from analysts and investors. The company has not announced financial guidance or preliminary Q2 figures in the call notice. The next confirmed steps are therefore the board’s consideration of the results, the exchange filing and the October 30 earnings call. Until those disclosures are made, the available information confirms the timing and participants, rather than the quarter’s outcome.